TITLE

ACE Inhibitors vs. Calcium Antagonists in Reducing Stroke

AUTHOR(S)
Walling, Anne D.
PUB. DATE
June 2001
SOURCE
American Family Physician;6/15/2001, Vol. 63 Issue 12, p2458
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents information on a study by the international Blood Pressure Lowering Treatment Trialists' Collaboration to estimate the benefits of angiotensin-converting enxyme (ACE) inhibitors and other medications for the reduction of stroke. Description of the study and its results; Conclusion that strong evidence supports the use of ACE inhibitors and calcium antagonists to prevent cardiovascular and cerebrovascular sequelae of hypertension.
ACCESSION #
12865805

 

Related Articles

  • Decitabine in Myelodysplastic Syndromes: A Viewpoint by Guillermo Garcia-Manero. Garcia-Manero, Guillermo // Drugs;2006, Vol. 66 Issue 7, p959 

    â–´ Delapril/manidipine 30mg/10mg is a new oral, once-daily, fixed combination of an ACE inhibitor and a dihydropyridine calcium-channel antagonist for the treatment of essential hypertension.â–´ In a dose-finding study in 400 patients with mild to moderate hypertension,...

  • Decitabine in Myelodysplastic Syndromes: A Viewpoint by Hussain Saba. Saba, Hussain // Drugs;2006, Vol. 66 Issue 7, p959 

    â–´ Delapril/manidipine 30mg/10mg is a new oral, once-daily, fixed combination of an ACE inhibitor and a dihydropyridine calcium-channel antagonist for the treatment of essential hypertension.â–´ In a dose-finding study in 400 patients with mild to moderate hypertension,...

  • Delapril/Manidipine. McCormack, Paul L.; Keating, Gillian M. // Drugs;2006, Vol. 66 Issue 7, p961 

    â–´ Delapril/manidipine 30mg/10mg is a new oral, once-daily, fixed combination of an ACE inhibitor and a dihydropyridine calcium-channel antagonist for the treatment of essential hypertension.â–´ In a dose-finding study in 400 patients with mild to moderate hypertension,...

  • Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies? Locatelli, Francesco; Del Vecchio, Lucia; Pozzoni, Pietro; D'Amico, Marco; Andrulli, Simeone // Kidney International Supplement;Jan2005, Issue 93, pS15 

    Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies?Over the recent years, it has been clearly documented that hypertension and proteinuria are the major factors responsible for progression of chronic kidney disease (CKD)....

  • Fixed-Dose Combination Lercanidipine/Enalapril. Hair, Philip I.; Scot, Lesley J.; Perry, Caroline M. // Drugs;2007, Vol. 67 Issue 1, p95 

    â–´ Lercanidipine, a dihydropyridine calcium channel blocker, and enalapril, an ACE inhibitor, are established antihypertensive agents. A fixed-dose tablet formulation of lercanidipine/enalapril is approved in Germany for the treatment of hypertension in patients not responding to...

  • Hypertension in Infantile Polycystic Renal Disease. Rahill, W. Joseph; Rubin, Mitchell I. // Clinical Pediatrics;Apr1972, Vol. 11 Issue 4, p232 

    Two infants with polycystic renal disease and severe hypertension had studies of renal function and antihypertensive therapy. One infant with adequate renal function died with uncontrolled hypertenson. The second infant's blood pressure approached normal; now three and one-half years of age, he...

  • Serum Calcium Level in Hypertension. Hazari, Mohammed Abdul Hannan; Arifuddin, Mehnaaz Sameera; Muzzakar, Syed; Reddy, Vontela Devender // North American Journal of Medical Sciences;Nov2012, Vol. 4 Issue 11, p569 

    Background: The alterations in extracellular calcium level may influence intracellular calcium level and possibly play a role in the pathogenesis of essential hypertension. Aim: The purpose was to find out the association between serum calcium levels and hypertension; and to compare the serum...

  • How well are hypertension and albuminuria treated in type II diabetic patients? Boero, R; Prodi, E; Elia, F; Porta, L; Martelli, S; Ferraro, L; Quarello, F // Journal of Human Hypertension;Jun2003, Vol. 17 Issue 6, p413 

    The purpose of this study was to assess the management of both hypertension and micro/macroalbuminuria in a cohort of type II diabetic patients. In the first 6 months of the year 2000, 5815 diabetic patients were identified through prescriptions for antidiabetic drugs in our sanitary district...

  • Takeda: hypertension hurdles.  // PharmaWatch: Monthly Review;Aug2006, Vol. 5 Issue 8, p16 

    The article reports that Takeda Pharmaceutical Co. Ltd. has advanced its investigational antihypertensive TAK-491 into phase II trials. The move is expected to accelerate Takeda's development of a follow-on product to its hypertension drug Blopress. Moreover, the company has surprised industry...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics